1. Enhanced browning of adipose tissue by mirabegron-microspheres.
- Author
-
Niu, Zheming, Hildebrand, Staffan, Kappes, Sebastian, Ali, Mohamed Ehab, Vogel, Matthias, Mikhael, Mickel, Ran, Danli, Kozak, Jan, Wiedner, Maria, Richter, Dirk F., Lamprecht, Alf, and Pfeifer, Alexander
- Subjects
- *
WHITE adipose tissue , *BROWN adipose tissue , *BETA adrenoceptors , *SYSTOLIC blood pressure , *UNCOUPLING proteins - Abstract
Thermogenic brown adipose tissue (BAT) has emerged as an attractive target for combating obesity. However, pharmacological activation of energy expenditure by BAT and/or induction of browning of white adipose tissue (WAT) has been hampered by cardiovascular side effects. To address these concerns, we developed polylactide- co -glycolide acid (PLGA) microspheres loaded with mirabegron (MIR), a selective beta-3 adrenergic receptor (ADRB3) agonist, to achieve sustained local induction and activation of thermogenic adipocytes. MIR-loaded PLGA microspheres (MIR-MS) effectively activated brown adipocytes and enhanced the thermogenic program in white adipocytes. Moreover, treating isolated inguinal WAT (iWAT) with MIR-MS resulted in increased expression of browning markers and elevated lipolysis mainly via ADRB3. In mice, injection of MIR-MS over four weeks induced browning of iWAT at the injection site. Importantly, local MIR-MS injection successfully mitigated unwanted cardiovascular risks, including high systolic blood pressure (SBP) and heart rate, as compared to MIR-treated mice. Finally, injecting MIR-MS into human subcutaneous WAT led to a significant induction of lipolysis and an increase in the expression of thermogenic marker uncoupling protein 1 (UCP1). Taken together, our findings indicate that MIR-MS function as a local drug release system that induces browning of human and murine subcutaneous WAT while mitigating undesirable cardiovascular effects. MIR-loaded PLGA microspheres provide a promising obesity treatment by inducing browning and thermogenic activation of white adipose tissue without eliciting cardiovascular side effects. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF